Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis

Dermatitis

Volumn 26, Issue 3, 2015, Pages 122-132

  Chia, Brian Keng Yong ^a   Tey, Hong Liang ^a  

^a NATIONAL SKIN CENTRE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; EMOLLIENT AGENT; PIMECROLIMUS; TACROLIMUS;

APPLICATION SITE REACTION; ARTICLE; ATOPIC DERMATITIS; BACTERIAL SKIN DISEASE; CANCER RISK; COST EFFECTIVENESS ANALYSIS; CREAM; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; META ANALYSIS; OINTMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN BURNING SENSATION; SKIN CANCER; SKIN INFECTION; SKIN IRRITATION; SYSTEMATIC REVIEW (TOPIC); ANALOGS AND DERIVATIVES; COST BENEFIT ANALYSIS; CUTANEOUS DRUG ADMINISTRATION; DERMATITIS, ATOPIC; ECONOMICS; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; CALCINEURIN INHIBITORS; COST-BENEFIT ANALYSIS; DERMATITIS, ATOPIC; HUMANS; TACROLIMUS; TREATMENT OUTCOME;

EID: 84929762022     PISSN: 17103568     EISSN: 21625220     Source Type: Journal    
DOI: 10.1097/DER.0000000000000118     Document Type: Article

References (79)

1. Van Der Meer JB, Glazenburg EJ, Mulder PG, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999;140(6):1114-1121.
2. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002;147(3):528-537.
3. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003;326(7403):1367.
4. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005;211(2):174-187.
5. Stuetz A, Baumann K, Grassberger M, et al. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol 2006;141(3):199-212.
6. Wong R, Lin AN. Efficacy of topical calcineurin inhibitors in vitiligo. Int J Dermatol 2013;52(4):491-496.
7. Wang C, Lin A. Efficacy of topical calcineurin inhibitors in psoriasis. J Cutan Med Surg 2014;18(1):8-14.
8. Horn EJ, Domm S, Katz HI, et al. Topical corticosteroids in psoriasis: strategies for improving safety. J Eur Acad Dermatol Venereol 2010;24(2):119-124.
9. Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician 2009;79(2):135-140.
10. Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002;109(3):539-546.
11. Nakagawa H. Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomised, double-blind clinical studies conducted in Japan. Clin Drug Investig 2006;26(5):235-246.
12. Doss N, Reitamo S, Dubertret L, et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. Br J Dermatol 2009;161(2):427-434.
13. Hebert AA, Koo J, Fowler J, et al. Desoximetasone 0.25% and tacrolimus 0.1% ointments versus tacrolimus alone in the treatment of atopic dermatitis. Cutis 2006;78(5):357-363.
14. Mandelin J, Remitz A, Virtanen H, et al. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial. Acta Derm Venereol 2010;90(2):170-174.
15. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002;109(3):547-555.
16. Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004;150(3):554-562.
17. Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005;152(6):1282-1289.
18. HofmanT, Cranswick N, Kuna P, et al. Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. Arch Dis Child 2006;91(11):905-910.
19. Bieber T, Vick K, Folster-Holst R, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy 2007;62(2):184-189.
20. Doss N, Kamoun MR, Dubertret L, et al. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment. Pediatr Allergy Immunol 2010;21(2 Pt 1):321-329.
21. Gradman J, Wolthers OD. Short-term growth in children with eczema during treatment with topical mometasone furoate and tacrolimus. Acta Paediatr 2007;96(8):1233-1237.
22. Torok HM, Maas-Irslinger R, Slayton RM. Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. Cutis 2003;72(2):161-166.
23. Hung SH, Lin YT, Chu CY, et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Ann Allergy Asthma Immunol 2007;98(1):51-56.
24. Sikder A, Al Mamun S, Khan RM, et al. Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitisVan open randomized comparative study. J Pak Assoc Dermatol 2005;15:304-312.
25. Breneman D, Fleischer AB Jr, Abramovits W, et al. Tacrolimus ointment with and without topical steroids in patients with moderate to severe atopic dermatitis. J Am Acad Dermatol 2006;54(3, Suppl 1):AB88 Abstr. P832.
26. Svensson A, Chambers C, Gånemo A, et al. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin 2011;27(7):1395-1406.
27. Ashcroft DM, Chen LC, Garside R, et al. Topical pimecrolimus for eczema. Cochrane Database Syst Rev 2007;4:CD005500.
28. Novartis (protocol CASM981C2314). A 4-week, randomized, multicenter, double-blind, vehicle-controlled, parallel-group clinical trial to evaluate the efficacy and safety of pimecrolimus cream 1% in the short-term treatment of patients with mild to moderate atopic dermatitis (eczema). 2005. Available at: www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%Fmain.jsp. Accessed August 1, 2006.
29. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46(4):495-504.
30. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003;142(2):155-162.
31. Luger T, Van Leent EJ, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144(4):788-794.
32. Barba J, Beirana A, Cohen V, et al. Pimecrolimus cream 1% is effective, well tolerated and safe in infants and children with atopic eczema of the face. J Eur Acad Dermatol Venereol 2003;17(Suppl 3:P2.35).
33. Novartis (protocol CASM981C2442). A 12-week multicenter study consisting of a 6-week double-blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the safety and efficacy of pimecrolimus cream 1% in mild to moderate head and neck atopic dermatitis of patients intolerant of topical corticosteroid. 2006. Available at: www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp. Accessed October 31, 2006.
34. Novartis (protocol ASM981C2402). An exploratory, randomized, double-blind, vehicle-controlled, multicenter, parallel dose study investigating the use of pimecrolimus cream 1% in mild to moderate atopic dermatitis patients who demonstrate a clinical insensitivity to topical glucocorticoids. 2005. Available at: www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp. Accessed August 1, 2006.
35. Kaufmann R, Bieber T, Helgesen AL, et al. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy 2006;61(3):375-381.
36. Leo HL, Bender BG, Leung SB, et al. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. J Allergy Clin Immunol 2004;114(3):691-693.
37. Staab D, Kaufmann R, Bräutigam M, et al. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol 2005;16(6):527-533.
38. Whalley D, Huels J, McKenna SP, et al. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. Pediatrics 2002;110(6):1133-1136.
39. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110(2):277-284.
40. Thaci D, Folster-Holst R, Hoger P, et al. Pimecrolimus cream 1% is effective in the treatment of atopic eczema in infants irrespective of clinical score. J Eur Acad Dermatol Venereol 2003;17(Suppl 3:P2.37).
41. Novartis (protocol CASM981C2322). A 4-week, randomized, multicenter, double-blind, vehicle-controlled, parallel-group clinical trial to evaluate the efficacy and safety of pimecrolimus cream 1% in the short-term treatment of patients with mild to moderate atopic dermatitis (eczema). 2005. Available at: www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp. Accessed August 1, 2006.
42. Novartis (protocol CASM981C2436). A multicenter, 5-week, randomized, double-blind, placebo-controlled, parallel group study exploring the effects of pimecrolimus cream 1% (twice daily application) vs. placebo control (twice daily application) on the molecular and cellular profile of adult male patients with atopic dermatitis. 2006. Available at: www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp. Accessed August 1, 2006.
43. Novartis (protocol ASM981C2315). A 26-week, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study to evaluate the incidence of atopic dermatitis flares when pimecrolimus cream 1% is used at the first signs and/or symptoms of atopic dermatitis and its safety and tolerability in children and adolescents 2Y17 years of age. 2005. Available at: www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp. Accessed August 1, 2006.
44. Novartis (protocol ASM981C2316). A 26-week, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study to evaluate the incidence of atopic dermatitis flares when pimecrolimus cream 1% is used at the first signs and/or symptoms of atopic dermatitis and its safety and tolerability in adults 18 years of age and older. 2005. Available at: www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp. Accessed August 1, 2006.
45. Novartis (protocol CASM981C1301) Norvatis CASM981C1301. Confirmatory study in pediatric patients with atopic dermatitis - multicenter, randomized, double-blind, parallel-group, vehicle-controlled study with a 26-weeks treatment phase to determine the efficacy, safety of pimecrolimus cream for long-term treatment of pediatric patients with atopic dermatitis. 2005. Available at: www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp. Accessed August 1, 2006.
46. Novartis (protocol CASM981C1303). Confirmatory study in adult patients with atopic dermatitis - multicenter, randomized, double-blind, parallel-group, vehicle-controlled study with a 26-week treatment phase to determine the efficacy, safety of pimecrolimus cream for long-term treatment of adult patients with atopic dermatitis. 2005. Available at: www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp. Accessed August 1, 2006.
47. Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002;205(3):271-277.
48. Siegfried E, Korman N, Molina C, et al. Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis. J Dermatolog Treat 2006;17(3):143-150.
49. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110(1 Pt 1):e2.
50. Novartis (protocol CASM981CUS03). A 6-month, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of pimecrolimus 1% cream twice daily vs. standard of care in the management of mild to severe atopic dermatitis in adults. 2005. Available at: www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp. Accessed August 1, 2006.
51. Novartis (protocol ASM981CDE10). A 24-week, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study on pimecrolimus cream 1% assessing the steroid-sparing effect in the long term management of pediatric patients with severe atopic dermatitis. 2005. Available at: www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp. Accessed August 1, 2006.
52. Luger TA, Lahfa M, Folster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004;15(3):169-178.
53. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004;51(4):515-525.
54. Paller AS, Lebwohl M, Fleischer AB Jr, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005;52(5):810-822.
55. Public Health Advisory for Elidel and Protopic (Oct 2005). Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm153956.htm. Accessed July 26, 2014.
56. Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol 2011;165(3):465-473.
57. Hui RL, Lide W, Chan J, et al. Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother 2009;43(12):1956-1963.
58. Schneeweiss S, Doherty M, Zhu S, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology 2009;219(1):7-21.
59. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007;127(4):808-816.
60. Arellano FM, Arana A, Wentworth CE, et al. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol 2009;123(5):1111-1116, 1116.e1-1116.e13.
61. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007;214(4):289-295.
62. Yokota K, Gill TJ 3rd, Shinozuka H. Effects of oral versus topical administration of cyclosporine on phorbol ester promotion of murine epidermal carcinogenesis. Cancer Res 1989;49(16):4586-4590.
63. Gschwendt M, Kittstein W, Marks F. Cyclosporin A inhibits phorbol ester-induced cellular proliferation and tumor promotion as well as phosphorylation of a 100-kd protein in mouse epidermis. Carcinogenesis 1987;8(2):203-207.
64. Tran C, Lübbe J, Sorg O, et al. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005;211(4):341-347.
65. Garside R, Stein K, Castelnuovo E, et al. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. Health Technol Assess 2005;9(29):iii, xi-xiii,1-230.
66. Pitt M, Garside R, Stein K. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br J Dermatol 2006;154(6):1137-1146.
67. Hjelmgren J, Svensson A, Jörgensen ET, et al. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data. Br J Dermatol 2007;156(5):913-921.
68. Abramovits W, Boguniewicz M, Prendergast MM, et al. Comparisons of efficacy and cost-effectiveness of topical immunomodulators in the management of atopic dermatitis. J Med Econ 2003;6:1-14.
69. Taneja C, Antaya RJ, Berger A, et al. Cost-effectiveness of tacrolimus ointment versus pimecrolimus cream in adults with atopic dermatitis. J Drugs Dermatol 2010;9(4):372-376.
70. Healy E, Bentley A, Fidler C, et al. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol 2011;164(2):387-395.
71. Thaci D, Chambers C, Sidhu M, et al. Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months. J Eur Acad Dermatol Venereol 2010;24(9):1040-1046.
72. Wollenberg A, Sidhu MK, Odeyemi I, et al. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2008;159(6):1322-1330.
73. Ellis CN, Drake LA, Prendergast MM, et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol 2003;48(4):553-563.
74. Meurer M, Lubbe J, Kapp A, et al. The role of pimecrolimus cream 1% (Elidel) in managing adult atopic eczema. Dermatology 2007;215(Suppl 1):18-26.
75. Ellis CN, Kahler KH, Grueger J, et al. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. Am J Clin Dermatol 2006;7(2):133-139.
76. Folland S, Goodman AC, Stano M. Chapter 4: economic efficiency and cost-benefit analysis. In: The Economics of Health and Health Care. 6th ed. Boston, MA: Prentice Hall; 2010.
77. Minutes of the Pediatric Advisory Committee meeting. March 22, 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM208036.pdf. Accessed June 21, 2014.
78. Minutes of the Pediatric Advisory Committee meeting. May 16, 2011. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM261384.pdf. Accessed June 21, 2014.
79. Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol 2013;14(3):163-178.